EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024
EyePoint Pharmaceuticals To Highlight DURAVYUTM Clinical And Regulatory Developments At R&D Day 2024
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –
根據與FDA的積極EOP2會議，LUGANO和LUCIA關鍵的非劣性試驗的第三階段試驗設計已經制定完畢，計劃於2024下半年開始試驗。
– Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy –
DAVIO 2第二階段臨床試驗觀察DURAVYU治療溼性年齡相關黃斑變性的安全性和療效的十二個月正面數據進一步證明其作爲持續六個月維持治療的潛力。 作爲持續六個月維持治療的潛力，DURAVYU在糖尿病性黃斑水腫（DME）的第二階段試驗已招滿。
– Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled –
DURAVYU在糖尿病性黃斑水腫（DME）方面的第二階段試驗已經完全招募。
– EyePoint to webcast its R&D Day event today at 8:00 a.m. ET –
EyePoint將於今天東部時間上午8:00通過網絡直播其研發日活動。
譯文內容由第三人軟體翻譯。